A role for STEAP2 in prostate cancer progression

Clinical and Experimental Metastasis

Volumn 31, Issue 8, 2014, Pages 909-920

  Whiteland, Helen ^a   Spencer Harty, Samantha ^b   Morgan, Claire ^a   Kynaston, Howard ^c   Thomas, David Hywel ^b   Bose, Pradeep ^d   Fenn, Neil ^d   Lewis, Paul ^a   Jenkins, Spencer ^a,c   Doak, Shareen H ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SINGLETON HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d MORRISTON HOSPITAL   (United Kingdom)

Author keywords

Carcinogenesis; Invasion; Metastasis; Migration; Prostate cancer; STEAP1; STEAP2

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 2; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MESSENGER RNA; OXIDOREDUCTASE; STEAP2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LNCAP CELL LINE; MALE; MICROARRAY ANALYSIS; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR INVASION; UPREGULATION; ADENOCARCINOMA; AGED; APOPTOSIS; CASE CONTROL STUDY; CELL MOTION; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE COURSE; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84917731124     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9679-9     Document Type: Article

References (36)

1. Cancer Statistics http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/prostate/incidence/#age. Accessed 15 Mar 2013
2. Ihlaseh‐Catalano SM, Drigo SA, Jesus C, Domingues MAC, Trindade Filho JCS, Camargo JLV et al (2013) STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma. Histopathology 63(5):678–685
3. Wright JL, Lange PH (2007) Newer potential biomarkers in prostate cancer. Rev Urol 9(4):207–213
4. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974
5. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 58(6):843–848
6. Duffy M, McGowan P, Gallagher W (2008) Cancer invasion and metastasis: changing views. J Pathol 214(3):283–293
7. Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123(24):4195–4200
8. Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278(1):16–27
9. Murphy G (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8(12):932–941
10. Brehmer B, Biesterfeld S, Jakse G (2003) Expression of matrix metalloproteinases (MMP-2 and-9) and their inhibitors (TIMP-1 and-2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 6(3):217–222
11. Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A (2004) Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol Rep 11(6):1187–1192
12. Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S (2008) Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem 283(10):6232–6240
13. Millimaggi D, Mari M, D’Ascenzo S, Carosa E, Jannini EA, Zucker S et al (2007) Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia (New York, NY) 9(4):349
14. Wang L, Jin Y, Arnoldussen YJ, Jonson I, Qu S, Mælandsmo GM et al (2010) STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res 70(14):5818
15. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F (2002) Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem 277(39):36689–36696
16. Ohgami RS, Campagna DR, McDonald A, Fleming MD (2006) The Steap proteins are metalloreductases. Blood 108(4):1388
17. Yamamoto T, Tamura Y, Kobayashi J-i, Kamiguchi K, Hirohashi Y, Miyazaki A et al (2013) Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumor growth via intercellular communication. Exp Cell Res 319(17):2617–2626
18. Moreaux J, Kassambara A, Hose D, Klein B (2012) STEAP1 is overexpressed in cancers: a promising therapeutic target. Biochem Biophys Res Commun 429(3):148–155
19. Gomes IM, Maia CJ, Santos CR (2012) STEAP proteins: from structure to applications in cancer therapy. Mol Cancer Res 10(5):573–587
20. Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison KJ, Perez-Villar JJ et al (2007) Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 67(12):5798
21. Lalani EN, Laniado ME, Abel PD (1997) Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 16(1–2):29–66
22. Smith P, Rhodes NP, Shortland AP, Fraser SP, Djamgoz M, Ke Y et al (1998) Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett 423(1):19–24
23. Bennett ES, Smith BA, Harper JM (2004) Voltage-gated Na + channels confer invasive properties on human prostate cancer cells. Pflügers Archiv 447(6):908–914
24. + channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol 150(4):1213
25. + channel activity in human prostate cancer cell lines of markedly different metastatic potential: distinguishing characteristics of PC-3 and LNCaP cells. Prostate 46(4):262–274
26. Prevarskaya N, Skryma R, Bidaux G, Flourakis M, Shuba Y (2007) Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ 14(7):1295–1304
27. De Mattia F, Gubser C, van Dommelen MMT, Visch HJ, Distelmaier F, Postigo A et al (2009) Human Golgi antiapoptotic protein modulates intracellular calcium fluxes. Mol Biol Cell 20(16):3638–3645
28. Kaarbo M, Kokk TI, Saatcioglu F (2007) Androgen signaling and its interactions with other signaling pathways in prostate cancer. BioEssays 29(12):1227–1238
29. Arnoldussen YJ, Saatcioglu F (2009) Dual specificity phosphatases in prostate cancer. Mol Cell Endocrinol 309(1):1–7
30. Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB (2001) Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20(31):4209
31. Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22(4):395–403
32. Royuela M, Arenas MI, Bethencourt FR, Fraile B, Paniagua R (2002) Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol 33(3):299–306
33. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59(2):279
34. Uzgare AR, Kaplan PJ, Greenberg NM (2003) Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 55(2):128–139
35. Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6(12):924–935
36. Grunewald T, Herbst SM, Heinze J, Burdach S (2011) Understanding tumor heterogeneity as functional compartments-superorganisms revisited. J Transl Med 9(1):79